Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination

Abstract

Background and aim Coronavirus Disease 2019 (COVID-19) has become a worldwide pandemic and is a threat to global health. Patients who experienced cytokine storms tend to have a high mortality rate. However, to date, no study has investigated the impact of cytokine storms. Materials and methods This retrospective cohort study included only COVID-19 positive patients hospitalized in a Private Hospital in West Jakarta between March and September 2020. All patients were not vaccinated during this period and treatment was based on the guidelines by the Ministry of Health Indonesia. A convenience sampling method was used and all patients who met the inclusion criteria were enrolled. Results The clinical outcome of COVID-19 patients following medical therapy was either cured (85.7%) or died (14.3%), with 14.3% patients reported to have cytokine storm, from which 23.1% led to fatalities. A plasma immunoglobulin (Gammaraas®) and/or tocilizumab (interleukin-6 receptor antagonist; Actemra®) injection was utilised to treat the cytokine storm while remdesivir and oseltamivir were administered to ameliorate COVID-19. Most (61.5%) patients who experienced the cytokine storm were male; mean age 60 years. Interestingly, all patients who experienced the cytokine storm had hypertension or/ and diabetes complication (100%). Fever, cough and shortness of breath were also the common symptoms (100.0%). Almost all (92.3%) patients with cytokine storm had to be treated in the intensive care unit (ICU). Most (76.9%) patients who had cytokine storm received hydroxychloroquine and all had antibiotics [1) azithromycin + levofloxacin or 2) meropenam for critically ill patients] and vitamins such as vitamins C and B-complex as well as mineral. Unfortunately, from this group, 23.1% patients died while the remaining 70% of patients recovered. A significant (p<0.05) correlation was established between cytokine storms and age, the presence of comorbidity, diabetes, hypertension, fever, shortness of breath, having oxygen saturation (SPO2) less than 93%, cold, fatigue, ward of admission, the severity of COVID-19 disease, duration of treatment as well as the use of remdesivir, Actemra® and Gammaraas®. Most patients recovered after receiving a combination treatment (oseltamivir + remdesivir + Antibiotics + Vitamin/Mineral) for approximately 11 days with a 90% survival rate. On the contrary, patients who received oseltamivir + hydroxychloroquine + Gammaraas® + antibiotics +Vitamin/Mineral, had a 83% survival rate after being admitted to the hospital for about ten days. Conclusion Factors influencing the development of a cytokine storm include age, duration of treatment, comorbidity, symptoms, type of admission ward and severity of infection. Most patients (76.92%) with cytokine storm who received Gammaraas®/Actemra®, survived although they were in the severe and critical levels (87.17%). Overall, based on the treatment duration and survival rate, the most effective therapy was a combination of oseltamivir + favipiravir + hydroxychloroquine + antibiotics + vitamins/minerals.

Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling

“…A key determinant factor of COVID19 progression is the uncontrolled dysregulation production of cytokines and chemokines, resulting in the development of a cytokine storm, systemic inflammation, and consequently multi-organ failure ( 2 ). The presence of the cytokine storm was associated with COVID-19 severity as previously reported ( 3 , 4 ), where the serum levels of cytokines in COVID-19 patients were significantly correlated with the severity of the disease and acted as warning indicators of the severity and progression of COVID-19.…”

Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities

“…Research about the mechanisms underlying COVID-19 immunopathology early identified IL-6 as a deleterious factor and proposed this cytokine as one of the main therapeutic targets to be blocked to improve patient survival and outcome. Following this direction, two IL-6 receptor antagonists, tocilizumab and sarilumab have been used in COVID-19 with variable outcomes ( 54 – 57 ). We found that IL-6 was significantly associated with death by COVID-19 only during the first wave leading us to question the role of this cytokine as a single biomarker associated with fatal outcomes.…”

Laboratory Findings and Clinical Outcomes of ICU-admitted COVID-19 Patients: A Retrospective Assessment of Particularities Identified among Romanian Minorities

“…Many COVID-19 patients who exhibit severe SARS-CoV-2 infection are admitted to critical care units and have very high concentrations of inflammatory markers and D-dimers in their serum samples [ 21 ]. When evaluating the results of blood tests on patients with severe SARS-CoV-2 infection, it was observed that a very large increase in cytokines, roughly equivalent to an increase of four times or more, is associated with an increased risk of mortality [ 22 ]. Additionally, the severity of COVID-19 may be impacted by a number of known and unknown variables, such as certain demographic features, racial disparities, the poverty status of the community, or an ethnic group such as the Roma population.…”